A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time...
Saved in:
| Published in | Nature medicine Vol. 29; no. 4; pp. 859 - 868 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Nature Publishing Group US
01.04.2023
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1078-8956 1546-170X 1546-170X |
| DOI | 10.1038/s41591-023-02226-6 |
Cover
| Abstract | One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0–5.3),
P
< 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7–6.4),
P
< 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83–7.60),
P
= 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials.
A machine learning model that uses longitudinal ctDNA metrics robustly predicts survival in two phase 3 trials of patients with metastatic NSCLC, which may improve therapy selection and risk stratification. |
|---|---|
| AbstractList | One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0–5.3), P < 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7–6.4), P < 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83–7.60), P = 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials. A machine learning model that uses longitudinal ctDNA metrics robustly predicts survival in two phase 3 trials of patients with metastatic NSCLC, which may improve therapy selection and risk stratification. One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0-5.3), P < 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7-6.4), P < 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83-7.60), P = 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials.One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0-5.3), P < 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7-6.4), P < 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83-7.60), P = 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials. One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0–5.3), P < 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7–6.4), P < 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83–7.60), P = 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials. One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0-5.3), P < 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7-6.4), P < 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83-7.60), P = 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials. One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal circulating tumor DNA (ctDNA) dynamics for the prediction of survival have generally been small or nonrandomized. We assessed ctDNA across 5 time points in 466 non-small-cell lung cancer (NSCLC) patients from the randomized phase 3 IMpower150 study comparing chemotherapy-immune checkpoint inhibitor (chemo-ICI) combinations and used machine learning to jointly model multiple ctDNA metrics to predict overall survival (OS). ctDNA assessments through cycle 3 day 1 of treatment enabled risk stratification of patients with stable disease (hazard ratio (HR) = 3.2 (2.0–5.3), P < 0.001; median 7.1 versus 22.3 months for high- versus low-intermediate risk) and with partial response (HR = 3.3 (1.7–6.4), P < 0.001; median 8.8 versus 28.6 months). The model also identified high-risk patients in an external validation cohort from the randomized phase 3 OAK study of ICI versus chemo in NSCLC (OS HR = 3.73 (1.83–7.60), P = 0.00012). Simulations of clinical trial scenarios employing our ctDNA model suggested that early ctDNA testing outperforms early radiographic imaging for predicting trial outcomes. Overall, measuring ctDNA dynamics during treatment can improve patient risk stratification and may allow early differentiation between competing therapies during clinical trials. A machine learning model that uses longitudinal ctDNA metrics robustly predicts survival in two phase 3 trials of patients with metastatic NSCLC, which may improve therapy selection and risk stratification. |
| Author | Nishio, Makoto Rode, Anja Oxnard, Geoffrey R. Reck, Martin Young, Amanda Zou, Wei Lipson, Doron Fine, Alexander D. Assaf, Zoe June F. Cummings, Craig Kennedy, Mark Patil, Namrata S. Lee, Mark Shames, David S. Schulze, Katja Freidin, Jonathan F. Polisecki, Eliana Fabrizio, David Socinski, Mark A. |
| Author_xml | – sequence: 1 givenname: Zoe June F. surname: Assaf fullname: Assaf, Zoe June F. email: assaf.zoe-june@gene.com organization: Genentech Inc – sequence: 2 givenname: Wei orcidid: 0000-0002-3639-9821 surname: Zou fullname: Zou, Wei organization: Genentech Inc – sequence: 3 givenname: Alexander D. surname: Fine fullname: Fine, Alexander D. organization: Foundation Medicine Inc – sequence: 4 givenname: Mark A. surname: Socinski fullname: Socinski, Mark A. organization: AdventHealth Cancer Institute – sequence: 5 givenname: Amanda orcidid: 0000-0002-2199-1873 surname: Young fullname: Young, Amanda organization: Foundation Medicine Inc – sequence: 6 givenname: Doron surname: Lipson fullname: Lipson, Doron organization: Foundation Medicine Inc – sequence: 7 givenname: Jonathan F. orcidid: 0000-0003-1821-8932 surname: Freidin fullname: Freidin, Jonathan F. organization: Foundation Medicine Inc – sequence: 8 givenname: Mark surname: Kennedy fullname: Kennedy, Mark organization: Foundation Medicine Inc – sequence: 9 givenname: Eliana surname: Polisecki fullname: Polisecki, Eliana organization: Foundation Medicine Inc – sequence: 10 givenname: Makoto surname: Nishio fullname: Nishio, Makoto organization: The Cancer Institute Hospital, Japanese Foundation for Cancer Research – sequence: 11 givenname: David surname: Fabrizio fullname: Fabrizio, David organization: Foundation Medicine Inc – sequence: 12 givenname: Geoffrey R. surname: Oxnard fullname: Oxnard, Geoffrey R. organization: Foundation Medicine Inc – sequence: 13 givenname: Craig surname: Cummings fullname: Cummings, Craig organization: Genentech Inc – sequence: 14 givenname: Anja surname: Rode fullname: Rode, Anja organization: F. Hoffman-La Roche AG – sequence: 15 givenname: Martin surname: Reck fullname: Reck, Martin organization: LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research – sequence: 16 givenname: Namrata S. surname: Patil fullname: Patil, Namrata S. organization: Genentech Inc – sequence: 17 givenname: Mark surname: Lee fullname: Lee, Mark organization: Genentech Inc – sequence: 18 givenname: David S. orcidid: 0000-0002-5900-1177 surname: Shames fullname: Shames, David S. email: shames.david@gene.com organization: Genentech Inc – sequence: 19 givenname: Katja orcidid: 0000-0003-3704-5651 surname: Schulze fullname: Schulze, Katja email: schulze.katja.ks2@gene.com organization: Genentech Inc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36928816$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtv1DAUhSNURB_wB1ggS2zYGOz4EWeFRi0vqYINSOws2_FMXTn24MdU_fd4yEChi4pF5Cg-38m55552RyEG23XPMXqNERFvMsVsxBD1pD19zyF_1J1gRjnEA_p-1N7RIKAYGT_uTnO-RggRxMYn3THhYy8E5iddWgEfw8aVOrmgPDAumepVcWEDSp1jAhefV1CrbCcwx8l6oHKOxqnSPty4cgVyTTu3a6gLYLZF5dJoA1pWmGflPTTWe-BrMzQqGJuedo_Xymf77HCedd_ev_t6_hFefvnw6Xx1CQ0dWIFq1BoJOpmB83FAmPcUUY21HtbaYmYtVxMzbVLKLNFMaSEIZdwMdk2xVZacdWTxrWGrbm9aFLlNblbpVmIk9w3KpUHZGpS_GpS8UW8Xalv1bCdjQ0nqjozKyX9vgruSm7hrhhgzTnFzeHVwSPFHtbnI2eV9CSrYWLPsBSIj50SQJn15T3oda2p7WFSYMkzGpnrxd6Q_WX5vsQn6RWBSzDnZ9f8NKu5Bxu1XF_djOf8wemg2t_-EjU13sR-gfgK2INKk |
| CitedBy_id | crossref_primary_10_1038_s41698_024_00704_9 crossref_primary_10_1200_PO_23_00718 crossref_primary_10_1002_ctm2_1619 crossref_primary_10_1038_s41698_025_00876_y crossref_primary_10_1016_j_tranon_2023_101735 crossref_primary_10_1016_j_canlet_2023_216365 crossref_primary_10_1097_RLI_0000000000001096 crossref_primary_10_3389_fonc_2024_1486310 crossref_primary_10_1007_s11517_024_03261_2 crossref_primary_10_1186_s43556_025_00257_8 crossref_primary_10_1038_s41598_024_68350_6 crossref_primary_10_1016_j_jlb_2024_100140 crossref_primary_10_1016_j_esmoop_2025_104479 crossref_primary_10_1200_CCI_24_00160 crossref_primary_10_1007_s00432_024_06030_8 crossref_primary_10_1002_cpt_3371 crossref_primary_10_1001_jamaoncol_2024_1779 crossref_primary_10_3390_ijms24108894 crossref_primary_10_3390_life13091915 crossref_primary_10_1016_j_clgc_2024_102087 crossref_primary_10_5937_medi57_46846 crossref_primary_10_3389_frai_2023_1227091 crossref_primary_10_1016_j_annonc_2023_12_007 crossref_primary_10_3389_fonc_2023_1308681 crossref_primary_10_1016_j_jlb_2023_100131 crossref_primary_10_1038_s41467_024_51536_x crossref_primary_10_1038_s41698_024_00797_2 crossref_primary_10_1002_pbc_31288 crossref_primary_10_1016_j_jncc_2024_01_008 crossref_primary_10_1177_17407745231213882 crossref_primary_10_1158_1078_0432_CCR_24_1883 crossref_primary_10_3390_biomedicines12102183 crossref_primary_10_1038_s41591_024_02851_9 crossref_primary_10_1186_s13046_024_02969_1 crossref_primary_10_1200_CCI_24_00224 crossref_primary_10_3389_fimmu_2024_1502206 crossref_primary_10_3389_fimmu_2025_1492296 crossref_primary_10_1016_j_lungcan_2024_108062 crossref_primary_10_1038_s41467_024_51316_7 crossref_primary_10_4274_tmsj_galenos_2024_2024_5_1 crossref_primary_10_3390_ijms241411547 crossref_primary_10_3389_pore_2024_1611817 crossref_primary_10_1200_PO_22_00445 crossref_primary_10_1002_cpt_3152 crossref_primary_10_1002_cpt_3153 crossref_primary_10_1002_cpt_3197 crossref_primary_10_1146_annurev_med_100223_090016 crossref_primary_10_3389_fimmu_2024_1509968 crossref_primary_10_1038_s41416_023_02445_1 crossref_primary_10_1158_1078_0432_CCR_23_1578 crossref_primary_10_3390_ijms252413669 crossref_primary_10_1016_j_tranon_2023_101702 crossref_primary_10_1073_pnas_2315168121 crossref_primary_10_1093_jnci_djae179 crossref_primary_10_1016_j_compbiomed_2025_109964 crossref_primary_10_1016_j_jtho_2024_06_014 crossref_primary_10_1080_14737159_2023_2252334 crossref_primary_10_1038_s41467_024_52923_0 crossref_primary_10_18632_oncotarget_28565 crossref_primary_10_1016_j_ccell_2024_08_013 crossref_primary_10_1016_j_soc_2023_12_026 crossref_primary_10_1200_PO_23_00289 crossref_primary_10_1158_1078_0432_CCR_24_0255 crossref_primary_10_1080_14737159_2023_2260755 crossref_primary_10_3390_ijms241310803 |
| Cites_doi | 10.1186/2051-1426-1-18 10.1371/journal.pone.0237802 10.1001/jamanetworkopen.2020.26921 10.1038/nrc.2017.7 10.1038/s41586-021-03642-9 10.21037/tlcr.2020.03.02 10.1200/JCO.2015.61.6870 10.1056/NEJMoa1809064 10.1038/s41598-019-53711-3 10.1038/s41591-018-0134-3 10.1056/NEJMoa1915745 10.1016/j.jtho.2021.07.009 10.1200/JCO.18.02052 10.1016/j.jmoldx.2018.05.004 10.1038/s43018-020-0096-5 10.1016/j.ejca.2008.10.026 10.1136/jitc-2020-001504 10.1001/jamaoncol.2019.3616 10.1016/S0140-6736(16)32455-2 10.1016/j.ejca.2017.10.017 10.1056/NEJMoa1917346 10.1002/sim.1802 10.1093/bioinformatics/btr511 10.1056/NEJMra1706174 10.1186/s13073-020-00770-1 10.3389/fonc.2020.595650 10.1001/jamaoncol.2019.1838 10.1158/0008-5472.CAN-12-0733 10.1016/S0140-6736(21)02098-5 10.1016/j.jclinepi.2008.02.008 10.1002/cjs.11542 10.1126/sciadv.abi8618 10.1056/NEJMoa1716948 10.1016/j.cell.2020.09.001 10.21037/atm.2019.03.20 10.1016/j.ejca.2018.10.011 10.1038/nature22364 10.1016/j.cct.2011.01.010 10.21037/jtd.2018.01.131 10.1016/S0140-6736(20)30934-X 10.1016/j.annonc.2020.11.007 10.1111/j.1467-9868.2005.00503.x 10.1038/s41591-019-0652-7 10.1126/scitranslmed.3007094 10.1200/PO.20.00046 10.1200/PO.20.00419 10.1200/PO.21.00057 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7X7 7XB 88A 88E 88I 8AO 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M2P M7N M7P MBDVC P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U RC3 7X8 5PM ADTOC UNPAY |
| DOI | 10.1038/s41591-023-02226-6 |
| DatabaseName | SpringerLink - Revues - OpenAccess CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep (ProQuest) AIDS and Cancer Research Abstracts SciTech Premium Collection (Proquest) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Medical Database Research Library (Proquest) Science Database (Proquest) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database (Proquest) Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals ProQuest SciTech Collection ProQuest Medical Library Animal Behavior Abstracts Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef Research Library Prep MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1546-170X |
| EndPage | 868 |
| ExternalDocumentID | 10.1038/s41591-023-02226-6 PMC10115641 36928816 10_1038_s41591_023_02226_6 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Roche (F. Hoffmann-La Roche Ltd) funderid: https://doi.org/10.13039/100004337 – fundername: ; |
| GroupedDBID | --- .-4 .55 .GJ 0R~ 123 1CY 29M 2FS 36B 39C 3O- 3V. 4.4 53G 5BI 5M7 5RE 5S5 70F 7X7 85S 88A 88E 88I 8AO 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AAEEF AARCD AAYOK AAYZH AAZLF ABAWZ ABCQX ABDBF ABDPE ABEFU ABJNI ABLJU ABOCM ABUWG ACBWK ACGFO ACGFS ACGOD ACIWK ACMJI ACPRK ACUHS ADBBV ADFRT AENEX AEUYN AFBBN AFKRA AFRAH AFSHS AGAYW AGCDD AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARMCB ASPBG AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI C6C CCPQU CS3 DB5 DU5 DWQXO EAD EAP EBC EBD EBS EE. EJD EMB EMK EMOBN EPL ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA GNUQQ GUQSH GX1 HCIFZ HMCUK HVGLF HZ~ IAO IEA IH2 IHR IHW INH INR IOF IOV ISR ITC J5H L7B LGEZI LK8 LOTEE M0L M1P M2O M2P M7P MK0 N9A NADUK NNMJJ NXXTH O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RIG RNS RNT RNTTT RVV SHXYY SIXXV SJN SNYQT SOJ SV3 TAE TAOOD TBHMF TDRGL TSG TUS UKHRP UQL X7M XJT YHZ ZGI ~8M AAYXX ABFSG ACSTC AEZWR AFANA AFHIU AHWEU AIXLP ALPWD ATHPR CITATION NFIDA PHGZM PHGZT PJZUB PPXIY PQGLB PUEGO CGR CUY CVF ECM EIF NPM 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7XB 8FD 8FK AGSTI C1K FR3 H94 K9. M7N MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U RC3 7X8 5PM ADTOC AETEA UNPAY |
| ID | FETCH-LOGICAL-c475t-a9bb084dc766970162404b1bb7fbe15ee6ad5c17045e3b5ab883456c7ef41eae3 |
| IEDL.DBID | UNPAY |
| ISSN | 1078-8956 1546-170X |
| IngestDate | Sun Oct 26 02:57:45 EDT 2025 Tue Sep 30 17:14:59 EDT 2025 Thu Oct 02 11:16:57 EDT 2025 Fri Oct 03 10:51:27 EDT 2025 Wed Feb 19 02:24:51 EST 2025 Thu Apr 24 22:54:04 EDT 2025 Wed Oct 01 04:32:44 EDT 2025 Fri Feb 21 02:37:37 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c475t-a9bb084dc766970162404b1bb7fbe15ee6ad5c17045e3b5ab883456c7ef41eae3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-5900-1177 0000-0002-3639-9821 0000-0003-1821-8932 0000-0003-3704-5651 0000-0002-2199-1873 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.nature.com/articles/s41591-023-02226-6.pdf |
| PMID | 36928816 |
| PQID | 2803145139 |
| PQPubID | 33975 |
| PageCount | 10 |
| ParticipantIDs | unpaywall_primary_10_1038_s41591_023_02226_6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10115641 proquest_miscellaneous_2803966383 proquest_journals_2803145139 pubmed_primary_36928816 crossref_primary_10_1038_s41591_023_02226_6 crossref_citationtrail_10_1038_s41591_023_02226_6 springer_journals_10_1038_s41591_023_02226_6 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-01 |
| PublicationDateYYYYMMDD | 2023-04-01 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Nature medicine |
| PublicationTitleAbbrev | Nat Med |
| PublicationTitleAlternate | Nat Med |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group US Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group US – name: Nature Publishing Group |
| References | Christensen (CR16) 2019; 37 Schröder, Culhane, Quackenbush, Haibe-Kains (CR49) 2011; 27 Garcia-Murillas (CR10) 2019; 5 Powles (CR15) 2021; 595 Horn (CR32) 2018; 379 Petrelli (CR5) 2019; 7 Chiou, Burotto (CR3) 2015; 33 CR38 Ferrara (CR25) 2018; 10 Bettegowda (CR24) 2014; 6 Corcoran, Chabner (CR7) 2018; 379 Guan, Tibshirani (CR40) 2020; 48 Eisenhauer (CR1) 2009; 45 Clark (CR45) 2018; 20 Bratman (CR22) 2020; 1 Sanz-Garcia, Zhao, Bratman, Siu (CR44) 2022; 8 Lau (CR12) 2020; 12 Chen (CR26) 2013; 1 Herbst (CR30) 2020; 383 CR41 Fridlyand, Kaiser, Fyfe (CR42) 2011; 32 Tie (CR9) 2019; 5 Socinski (CR27) 2018; 378 Gutzmer (CR33) 2020; 395 Tazdait (CR4) 2018; 88 Buder, Hochmair, Setinek, Pirker, Filipits (CR20) 2020; 9 CR19 Socinski (CR28) 2021; 16 Ricciuti (CR23) 2021; 9 Razavi (CR37) 2019; 25 Nabet (CR43) 2020; 183 Fojo, Noonan (CR2) 2012; 72 Beyersmann, Gastmeier, Wolkewitz, Schumacher (CR47) 2008; 61 Zou, Hastie (CR39) 2005; 67 Balar (CR31) 2017; 389 Kuang (CR14) 2021; 10 Felip (CR29) 2021; 398 Woodhouse (CR46) 2020; 15 Penciana, D’Agostino (CR48) 2004; 23 Finn (CR34) 2020; 382 Wan (CR8) 2017; 17 Osumi, Shinozaki, Yamaguchi, Zembutsu (CR18) 2019; 9 Nie (CR6) 2019; 106 Magbanua (CR17) 2021; 32 Cullinane (CR13) 2020; 3 Yaung (CR36) 2020; 4 Cheng (CR21) 2021; 16 Gandara (CR35) 2018; 24 Abbosh (CR11) 2017; 545 SJ Yaung (2226_CR36) 2020; 4 TA Clark (2226_CR45) 2018; 20 J Tie (2226_CR9) 2019; 5 E Felip (2226_CR29) 2021; 398 RS Finn (2226_CR34) 2020; 382 T Powles (2226_CR15) 2021; 595 DR Gandara (2226_CR35) 2018; 24 JCM Wan (2226_CR8) 2017; 17 M Tazdait (2226_CR4) 2018; 88 R Gutzmer (2226_CR33) 2020; 395 B Ricciuti (2226_CR23) 2021; 9 R Woodhouse (2226_CR46) 2020; 15 P Razavi (2226_CR37) 2019; 25 RB Corcoran (2226_CR7) 2018; 379 R Ferrara (2226_CR25) 2018; 10 E Sanz-Garcia (2226_CR44) 2022; 8 MJ Penciana (2226_CR48) 2004; 23 F Petrelli (2226_CR5) 2019; 7 H Osumi (2226_CR18) 2019; 9 A Buder (2226_CR20) 2020; 9 H Zou (2226_CR39) 2005; 67 P-P Kuang (2226_CR14) 2021; 10 2226_CR38 L Guan (2226_CR40) 2020; 48 BY Nabet (2226_CR43) 2020; 183 AV Balar (2226_CR31) 2017; 389 EA Eisenhauer (2226_CR1) 2009; 45 J Beyersmann (2226_CR47) 2008; 61 C Bettegowda (2226_CR24) 2014; 6 MS Schröder (2226_CR49) 2011; 27 C Abbosh (2226_CR11) 2017; 545 ML Cheng (2226_CR21) 2021; 16 E Lau (2226_CR12) 2020; 12 2226_CR41 MA Socinski (2226_CR27) 2018; 378 J Fridlyand (2226_CR42) 2011; 32 MJM Magbanua (2226_CR17) 2021; 32 2226_CR19 VL Chiou (2226_CR3) 2015; 33 L Horn (2226_CR32) 2018; 379 R-C Nie (2226_CR6) 2019; 106 RS Herbst (2226_CR30) 2020; 383 E Christensen (2226_CR16) 2019; 37 T-T Chen (2226_CR26) 2013; 1 C Cullinane (2226_CR13) 2020; 3 AT Fojo (2226_CR2) 2012; 72 SV Bratman (2226_CR22) 2020; 1 MA Socinski (2226_CR28) 2021; 16 I Garcia-Murillas (2226_CR10) 2019; 5 37059837 - Nat Med. 2023 Apr;29(4):797-798 |
| References_xml | – volume: 1 start-page: 18 year: 2013 ident: CR26 article-title: Statistical issues and challenges in immuno-oncology publication-title: J. Immunother. Cancer doi: 10.1186/2051-1426-1-18 – volume: 15 start-page: e0237802 year: 2020 ident: CR46 article-title: Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin publication-title: PLoS ONE doi: 10.1371/journal.pone.0237802 – volume: 3 start-page: e2026921 year: 2020 ident: CR13 article-title: Association of circulating tumor DNA with disease-free survival in breast cancer publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2020.26921 – volume: 17 start-page: 223 year: 2017 end-page: 238 ident: CR8 article-title: Liquid biopsies come of age: towards implementation of circulating tumour DNA publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.7 – volume: 595 start-page: 432 year: 2021 end-page: 437 ident: CR15 article-title: ctDNA guiding adjuvant immunotherapy in urothelial carcinoma publication-title: Nature doi: 10.1038/s41586-021-03642-9 – volume: 9 start-page: 239 year: 2020 end-page: 245 ident: CR20 article-title: EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib publication-title: Transl. Lung Cancer Res. doi: 10.21037/tlcr.2020.03.02 – volume: 33 start-page: 3541 year: 2015 end-page: 3543 ident: CR3 article-title: Pseudoprogression and immune-related response in solid tumors publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.61.6870 – volume: 379 start-page: 2220 year: 2018 end-page: 2229 ident: CR32 article-title: First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809064 – volume: 9 year: 2019 ident: CR18 article-title: Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer publication-title: Sci. Rep. doi: 10.1038/s41598-019-53711-3 – volume: 24 start-page: 1441 year: 2018 end-page: 1448 ident: CR35 article-title: Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab publication-title: Nat. Med. doi: 10.1038/s41591-018-0134-3 – volume: 382 start-page: 1894 year: 2020 end-page: 1905 ident: CR34 article-title: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1915745 – volume: 16 start-page: 1909 year: 2021 end-page: 1924 ident: CR28 article-title: IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2021.07.009 – ident: CR19 – volume: 37 start-page: 1547 year: 2019 end-page: 1557 ident: CR16 article-title: Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.02052 – volume: 20 start-page: 686 year: 2018 end-page: 702 ident: CR45 article-title: Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA publication-title: J. Mol. Diagn. doi: 10.1016/j.jmoldx.2018.05.004 – volume: 1 start-page: 873 year: 2020 end-page: 881 ident: CR22 article-title: Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab publication-title: Nat. Cancer doi: 10.1038/s43018-020-0096-5 – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: CR1 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 9 start-page: e001504 year: 2021 ident: CR23 article-title: Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small-cell lung cancer (NSCLC) publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001504 – volume: 5 start-page: 1710 year: 2019 ident: CR9 article-title: Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.3616 – volume: 389 start-page: 67 year: 2017 end-page: 76 ident: CR31 article-title: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(16)32455-2 – volume: 88 start-page: 38 year: 2018 end-page: 47 ident: CR4 article-title: Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2017.10.017 – volume: 383 start-page: 1328 year: 2020 end-page: 1339 ident: CR30 article-title: Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1917346 – volume: 23 start-page: 2109 year: 2004 end-page: 2123 ident: CR48 article-title: Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation publication-title: Stat. Med. doi: 10.1002/sim.1802 – volume: 27 start-page: 3206 year: 2011 end-page: 3208 ident: CR49 article-title: survcomp: an R/bioconductor package for performance assessment and comparison of survival models publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr511 – volume: 379 start-page: 1754 year: 2018 end-page: 1765 ident: CR7 article-title: Application of cell-free DNA analysis to cancer treatment publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1706174 – volume: 12 year: 2020 ident: CR12 article-title: Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression publication-title: Genome Med. doi: 10.1186/s13073-020-00770-1 – volume: 10 start-page: 595650 year: 2021 ident: CR14 article-title: Circulating tumor DNA analyses as a potential marker of recurrence and effectiveness of adjuvant chemotherapy for resected non-small-cell lung cancer publication-title: Front. Oncol. doi: 10.3389/fonc.2020.595650 – volume: 5 start-page: 1473 year: 2019 ident: CR10 article-title: Assessment of molecular relapse detection in early-stage breast cancer publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.1838 – volume: 72 start-page: 5151 year: 2012 end-page: 5157 ident: CR2 article-title: Why RECIST works and why it should stay—counterpoint publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-0733 – volume: 398 start-page: 1344 year: 2021 end-page: 1357 ident: CR29 article-title: Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)02098-5 – volume: 61 start-page: 1216 year: 2008 end-page: 1221 ident: CR47 article-title: An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation publication-title: J. Clin. Epidemiol. doi: 10.1016/j.jclinepi.2008.02.008 – volume: 48 start-page: 447 year: 2020 end-page: 470 ident: CR40 article-title: Post model‐fitting exploration via a ‘next‐door’ analysis publication-title: Can. J. Statist. doi: 10.1002/cjs.11542 – volume: 8 start-page: eabi8618 year: 2022 ident: CR44 article-title: Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges publication-title: Sci. Adv. doi: 10.1126/sciadv.abi8618 – volume: 378 start-page: 2288 year: 2018 end-page: 2301 ident: CR27 article-title: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716948 – volume: 183 start-page: 363 year: 2020 end-page: 376 ident: CR43 article-title: Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition publication-title: Cell doi: 10.1016/j.cell.2020.09.001 – volume: 7 start-page: 154 year: 2019 end-page: 154 ident: CR5 article-title: Surrogate endpoints in immunotherapy trials for solid tumors publication-title: Ann. Transl. Med. doi: 10.21037/atm.2019.03.20 – volume: 106 start-page: 1 year: 2019 end-page: 11 ident: CR6 article-title: Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2018.10.011 – volume: 545 start-page: 446 year: 2017 end-page: 451 ident: CR11 article-title: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution publication-title: Nature doi: 10.1038/nature22364 – ident: CR38 – volume: 32 start-page: 446 year: 2011 end-page: 452 ident: CR42 article-title: Analysis of tumor burden versus progression-free survival for phase II decision making publication-title: Contemp. Clin. Trials doi: 10.1016/j.cct.2011.01.010 – volume: 10 start-page: S1564 year: 2018 end-page: S1580 ident: CR25 article-title: Do immune checkpoint inhibitors need new studies methodology? publication-title: J. Thorac. Dis. doi: 10.21037/jtd.2018.01.131 – volume: 395 start-page: 1835 year: 2020 end-page: 1844 ident: CR33 article-title: Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(20)30934-X – volume: 32 start-page: 229 year: 2021 end-page: 239 ident: CR17 article-title: Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.11.007 – volume: 67 start-page: 301 year: 2005 end-page: 320 ident: CR39 article-title: Regularization and variable selection via the elastic net publication-title: J. R. Statist. Soc. Ser. B doi: 10.1111/j.1467-9868.2005.00503.x – volume: 25 start-page: 1928 year: 2019 end-page: 1937 ident: CR37 article-title: High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants publication-title: Nat. Med. doi: 10.1038/s41591-019-0652-7 – volume: 6 start-page: 224ra24 year: 2014 ident: CR24 article-title: Detection of circulating tumor DNA in early- and late-stage human malignancies publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3007094 – ident: CR41 – volume: 4 start-page: 1271 year: 2020 end-page: 1279 ident: CR36 article-title: Clonal hematopoiesis in late-stage non-small-cell lung cancer and its impact on targeted panel next-generation sequencing publication-title: JCO Precis. Oncol. doi: 10.1200/PO.20.00046 – volume: 16 start-page: 393 year: 2021 end-page: 402 ident: CR21 article-title: Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC publication-title: JCO Precis. Oncol. doi: 10.1200/PO.20.00419 – volume: 389 start-page: 67 year: 2017 ident: 2226_CR31 publication-title: Lancet doi: 10.1016/S0140-6736(16)32455-2 – ident: 2226_CR19 doi: 10.1200/PO.21.00057 – volume: 48 start-page: 447 year: 2020 ident: 2226_CR40 publication-title: Can. J. Statist. doi: 10.1002/cjs.11542 – volume: 33 start-page: 3541 year: 2015 ident: 2226_CR3 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.61.6870 – volume: 61 start-page: 1216 year: 2008 ident: 2226_CR47 publication-title: J. Clin. Epidemiol. doi: 10.1016/j.jclinepi.2008.02.008 – volume: 379 start-page: 2220 year: 2018 ident: 2226_CR32 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1809064 – volume: 595 start-page: 432 year: 2021 ident: 2226_CR15 publication-title: Nature doi: 10.1038/s41586-021-03642-9 – volume: 9 start-page: e001504 year: 2021 ident: 2226_CR23 publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001504 – volume: 88 start-page: 38 year: 2018 ident: 2226_CR4 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2017.10.017 – volume: 379 start-page: 1754 year: 2018 ident: 2226_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1706174 – volume: 9 start-page: 239 year: 2020 ident: 2226_CR20 publication-title: Transl. Lung Cancer Res. doi: 10.21037/tlcr.2020.03.02 – volume: 72 start-page: 5151 year: 2012 ident: 2226_CR2 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-0733 – volume: 17 start-page: 223 year: 2017 ident: 2226_CR8 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.7 – volume: 383 start-page: 1328 year: 2020 ident: 2226_CR30 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1917346 – volume: 545 start-page: 446 year: 2017 ident: 2226_CR11 publication-title: Nature doi: 10.1038/nature22364 – volume: 4 start-page: 1271 year: 2020 ident: 2226_CR36 publication-title: JCO Precis. Oncol. doi: 10.1200/PO.20.00046 – volume: 3 start-page: e2026921 year: 2020 ident: 2226_CR13 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2020.26921 – volume: 32 start-page: 446 year: 2011 ident: 2226_CR42 publication-title: Contemp. Clin. Trials doi: 10.1016/j.cct.2011.01.010 – volume: 16 start-page: 1909 year: 2021 ident: 2226_CR28 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2021.07.009 – volume: 12 year: 2020 ident: 2226_CR12 publication-title: Genome Med. doi: 10.1186/s13073-020-00770-1 – volume: 10 start-page: S1564 year: 2018 ident: 2226_CR25 publication-title: J. Thorac. Dis. doi: 10.21037/jtd.2018.01.131 – volume: 27 start-page: 3206 year: 2011 ident: 2226_CR49 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr511 – volume: 20 start-page: 686 year: 2018 ident: 2226_CR45 publication-title: J. Mol. Diagn. doi: 10.1016/j.jmoldx.2018.05.004 – volume: 9 year: 2019 ident: 2226_CR18 publication-title: Sci. Rep. doi: 10.1038/s41598-019-53711-3 – volume: 378 start-page: 2288 year: 2018 ident: 2226_CR27 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1716948 – volume: 395 start-page: 1835 year: 2020 ident: 2226_CR33 publication-title: Lancet doi: 10.1016/S0140-6736(20)30934-X – volume: 45 start-page: 228 year: 2009 ident: 2226_CR1 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 398 start-page: 1344 year: 2021 ident: 2226_CR29 publication-title: Lancet doi: 10.1016/S0140-6736(21)02098-5 – volume: 32 start-page: 229 year: 2021 ident: 2226_CR17 publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.11.007 – volume: 183 start-page: 363 year: 2020 ident: 2226_CR43 publication-title: Cell doi: 10.1016/j.cell.2020.09.001 – volume: 7 start-page: 154 year: 2019 ident: 2226_CR5 publication-title: Ann. Transl. Med. doi: 10.21037/atm.2019.03.20 – volume: 1 start-page: 18 year: 2013 ident: 2226_CR26 publication-title: J. Immunother. Cancer doi: 10.1186/2051-1426-1-18 – volume: 8 start-page: eabi8618 year: 2022 ident: 2226_CR44 publication-title: Sci. Adv. doi: 10.1126/sciadv.abi8618 – volume: 15 start-page: e0237802 year: 2020 ident: 2226_CR46 publication-title: PLoS ONE doi: 10.1371/journal.pone.0237802 – ident: 2226_CR41 – volume: 106 start-page: 1 year: 2019 ident: 2226_CR6 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2018.10.011 – volume: 25 start-page: 1928 year: 2019 ident: 2226_CR37 publication-title: Nat. Med. doi: 10.1038/s41591-019-0652-7 – volume: 67 start-page: 301 year: 2005 ident: 2226_CR39 publication-title: J. R. Statist. Soc. Ser. B doi: 10.1111/j.1467-9868.2005.00503.x – volume: 382 start-page: 1894 year: 2020 ident: 2226_CR34 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1915745 – volume: 5 start-page: 1473 year: 2019 ident: 2226_CR10 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.1838 – volume: 1 start-page: 873 year: 2020 ident: 2226_CR22 publication-title: Nat. Cancer doi: 10.1038/s43018-020-0096-5 – volume: 5 start-page: 1710 year: 2019 ident: 2226_CR9 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.3616 – volume: 16 start-page: 393 year: 2021 ident: 2226_CR21 publication-title: JCO Precis. Oncol. doi: 10.1200/PO.20.00419 – volume: 24 start-page: 1441 year: 2018 ident: 2226_CR35 publication-title: Nat. Med. doi: 10.1038/s41591-018-0134-3 – ident: 2226_CR38 – volume: 6 start-page: 224ra24 year: 2014 ident: 2226_CR24 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3007094 – volume: 10 start-page: 595650 year: 2021 ident: 2226_CR14 publication-title: Front. Oncol. doi: 10.3389/fonc.2020.595650 – volume: 23 start-page: 2109 year: 2004 ident: 2226_CR48 publication-title: Stat. Med. doi: 10.1002/sim.1802 – volume: 37 start-page: 1547 year: 2019 ident: 2226_CR16 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.18.02052 – reference: 37059837 - Nat Med. 2023 Apr;29(4):797-798 |
| SSID | ssj0003059 |
| Score | 2.6436844 |
| Snippet | One of the great challenges in therapeutic oncology is determining who might achieve survival benefits from a particular therapy. Studies on longitudinal... |
| SourceID | unpaywall pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 859 |
| SubjectTerms | 631/114/1305 631/67/1857 692/308/2779 692/699/67/1612/1350 Biomarkers, Tumor - genetics Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy Circulating Tumor DNA - genetics Clinical trials Deoxyribonucleic acid DNA Health services Humans Immune checkpoint inhibitors Infectious Diseases Learning algorithms Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Machine learning Metabolic Diseases Metastases Metastasis Molecular Medicine Neurosciences Non-small cell lung carcinoma Patients Risk Risk groups Small cell lung carcinoma Survival Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9RAEB_qFa0-iFar0Sor-GaX5nOzeRA5taUIPUQs9C3sV-tBLjnvEqT_vTP5qkfh8DXZfOzO7OxvdmbnB_A-1JnV0qbcGHRXY5dYngnn8xDRhgikik17bu18Js4u4m-XyeUOzIazMJRWOdjE1lDbytAe-TGxKBGrbJR9Wv7mxBpF0dWBQkP11Ar2Y1ti7B7shlQZawK7n09m33-Mthm1O-uyECWX6Br0x2j8SB6vcSmjLKCQ4poISrjYXKru4M-7aZRjLPUR7DXlUt38UUXxz3J1-gQe9ziTTTvFeAo7rtyH-x3z5M0-PDjvY-rPYDVlRUWsRY0lhixm5ivTcnqV16xuFtWKfZ1NOa12lrW8OUz1IsULtI3L1g3aG9RYNi_ZwtWKDinNDSurkq8X-G-cogOsQLPCDCnZ6jlcnJ78_HLGeyYGbuI0qbnKtPZlbE0qRJYiSkQcEOtA6_RKuyBxTiibmCBFfOginSgtZYTIzKTuKg6cctEBTPCj7iUw40dK2cxEFn3LLLQqznDcfZ0QdDNB5EEwDHpu-jLlxJZR5G24PJJ5J6gcBZW3gsqFBx_GZ5ZdkY6trQ8HWeb9hF3nt-rlwbvxNk41GiFVuqrp2qB3iD69By860Y-fi0QWShngy-WGUowNqIz35p1y_qst5x0QKhdx4MHRoD-3_7WtG0ejjv1Hr19t7_VreBi2qk85SYcwqVeNe4Nwq9Zv-zn0F41IJOs priority: 102 providerName: ProQuest – databaseName: SpringerLink - Revues - OpenAccess dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEB7ShL4OpU1fbtKiQm9dkZUly9Jx2TSEQHJqIDejV9oFrzd4bUr-fUe21-2yENqrJes1I80njTQfwJfUam-Vz6lzuF0VIfNUyzClKaINyZQRrnu3dnklz6_FxU12sweTzVuYLf99F7p7jSYm3s5Jo78RwQKVj-BAoWJGvoK5nI_rLmqu7m8YKqoQ9g9PZLCUk90yts3QDrbcvSI5-kmfw9O2ujP3v0xZ_mWKzl7CiwFDklkv9FewF6pDeNyzSt4fwpPLwV_-GuoZKVeRkaj1kf2KuEXtOr6u6gdp2uWqJqdXMxotmScdJw4xg7jwQzyiJesW1xLURrKoyDI0Jj5AWjhSrSq6XmLbaDz5JyUuGcRFBarfwPXZt-_zczqwLFAn8qyhRls7VcK7XEqdIwJEGy8ssza_tYFlIUjjM8dyxH6B28xYpTiiLpeHW8GCCfwt7GOl4T0QN-XGeO24x32jTr0RGsd9arMIyxzjCbDNoBduCEEemTDKonOFc1X0gipQUEUnqEIm8HX8564PwPFg7uONLIthMq6LSMAVCYm5TuDzmIzTKI6QqcKq7fPgzg_36wm860U_VselTpViWLjaUooxQwzRvZ1SLX52obpZRNxSsAQmG_35066HujEZdewfev3h_0o_gmdpNxXi_aNj2G_qNnxEaNXYT92M-g02VReu priority: 102 providerName: Springer Nature |
| Title | A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer |
| URI | https://link.springer.com/article/10.1038/s41591-023-02226-6 https://www.ncbi.nlm.nih.gov/pubmed/36928816 https://www.proquest.com/docview/2803145139 https://www.proquest.com/docview/2803966383 https://pubmed.ncbi.nlm.nih.gov/PMC10115641 https://www.nature.com/articles/s41591-023-02226-6.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1546-170X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: AFBBN dateStart: 20190101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 1546-170X dateEnd: 20241105 omitProxy: true ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: 7X7 dateStart: 20210101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1546-170X dateEnd: 20241105 omitProxy: true ssIdentifier: ssj0003059 issn: 1546-170X databaseCode: BENPR dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED9trfh64GN8FUZlJN6YSxInjvPYllUT0qoJUVGeIttxoSJNqzYRGn8953xBGZrYU6TkkvguZ_vn3Pl-AG88FSVKJCHVGpervgkSGnHjUA_RBneF9HW5b-18ys9m_od5MD8A3uyFKZP2y5KW5TDdZIe92-FEY3N0PBt1RMhA-WCTLA6hywPE4B3ozqYXwy9VgqGgIippWxEecOqGzrzeLeMw8Y8H7c9IV2Dm1WzJNmR6D-4U2UZe_pBp-sesNHkAnxt9qmSU74MiVwP9869SjzdX-CHcr4EqGVaSj-DAZEdwq6KuvDyC2-d1UP4xbIckXVvaoyKxFFtEL7e6JAXLvpK8WK235P10SO10mZCSeIfI2ifwhP0PTHYFDljo8mSZkZXJpd3ltNQkW2d0t0KtqQ0vkBTHJaKtl26fwGxy-ml8RmsqB6r9MMipjJRyhJ_okPMoRJiJQMJXrlLhQhk3MIbLJND4qfzAMBVIJQRDaKdDs_BdIw17Ch18qXkORDtMyiTSLMHFaeQl0o_QUo4KLPbTLuuB23zOWNd1zi3dRhqX8XYm4sq0MZo2Lk0b8x68be_ZVFU-rpU-brwkrnv8LrYsX5b1mEU9eN1exr5qLSQzsy4qGVxeMoGNfFY5Vfs6xiNPCBcfLvbcrRWwdcD3r2TLb2U9cNfCeu67PThpPPN3u65T46T13v_Q-sXNxF_CXa90XpvkdAydfFuYV4jfctWHw3Ae9qE7nIxGUzyOTqcXH_HsmI_7dUf-BfLuQTo |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4am2DwgGDAKAwwEjwxa03sJPbDhArb1LG1QmiT9hZ8G6vUpqVtNPXP8ds4zm1Ukype9po4ie1zz_E5H8CHUEurhU2oMRiuchdZKmPXpiF6G3EgFDdF3VqvH3fP-beL6GIN_tS1MP5YZa0TC0Vtx8b_I9_zKEoeVZbJz5Pf1KNG-exqDaGhKmgFu1-0GKsKO07c4hpDuNn-8QHS-2MYHh2efe3SCmWAGp5Ec6qk1m3BrUniWCboAaGN4zrQOrnULoici5WNTJCg7-OYjpQWgqHXYRJ3yQOnHMP33oMNzrjE4G_jy2H_-4_GFqA0yfLUo6ACQ5GqbKfNxN4MTac_dRT6PCo6QTReNo23_N3bxzab3O0j2MyziVpcq-HwH_N49AQeV34t6ZSM-BTWXLYF90uky8UWPOhVOfxnMO2Q4dijJOXWI3IRM5iaAkMs-0Xm-Wg8JQf9DvXW1ZICp4eoioXwgv9tTGY56jeUEDLIyMjNlS-KGhiSjTM6G-HcqM9GkCGqMWI8U0-fw_md0OQFrONH3Usgps2UstIwi7GsDK3iEve9rSPvKpqAtSCoNz01VVt0j84xTIv0PBNpSagUCZUWhErjFnxqnpmUTUFWjt6paZlWCmKW3rBzC943t1G0_Q6pzI3zcgxGo0zgJLdL0jefY7EMhQjw5WKJKZoBvm348p1scFW0Dw98FBDzoAW7Nf_czGvVMnYbHvuPVb9avep3sNk9652mp8f9k9fwMCzEwJ-H2oH1-TR3b9DVm-u3lTwR-HnXIvwXsBdiYQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEAMeEAwYhQFGgidmtYlzsR8QqijVxljFA5P6lvlWVqlNS5No6l_j13FObqOaVPGy18RJbJ-Lv5Nz7I-Q976WVgsbM2MgXA1caJmMXI_5gDYiT6jAlPvWzkbR8XnwbRyOd8ifZi8MllU2PrF01HZh8B95F1mUkFWWy-6kLov4MRh-Xv5myCCFmdaGTqNSkVO3voLwLft0MgBZf_D94defX45ZzTDATBCHOVNS654IrImjSMaAfmB9C7SndTzRzgudi5QNjRcD7nFch0oLwQFxmNhNAs8px-G9d8jdmHOJ5YTxuA320I5kVe8omIAgpN6w0-Oim8GiifVGPmZQAf6waHNRvIF0bxZstlnbh-R-kS7V-krNZv8sjMPH5FGNaGm_UsEnZMel--RexXG53id7Z3X2_ilZ9elsgfxIhUUuLmqmK1Oyh6W_aF7MFys6GPUZrquWlgw9VNXKAxfwhzHNCvBsYBt0mtK5yxVuh5oami5Sls2hbwzzEHQGDowaVOfVM3J-KxJ5Tnbho-4FoabHlbLScAtRrPStCiTMe0-HCBKNxzvEayY9MfWB6MjLMUvKxDwXSSWoBASVlIJKog752D6zrI4D2dr6sJFlUruGLLlW5A55194Go8YZUqlbFFUbiEO5gE4eVKJvP8cj6QvhwcvFhlK0DfDA8M076fSyPDjcQ_wfBV6HHDX6c92vbcM4anXsP0b9cvuo35I9MNzk-8no9BV54JdWgIVQh2Q3XxXuNWC8XL8pjYmSi9u23r_t0F_7 |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-NTnw98DEGFAYyEm_MJYkTx3msgGlCWsUDFeUp8lehWppWbSI0_nrOzgeUoYm9Jhc7dznbP-fO9wN4HanMKGFSqjVuV2ObGJpxG9AI0QYPhYy1P7d2NuGn0_jjLJntAe_OwvikfV_S0k_TXXbY2y0uNC5HJ3JRR4QMlI_WZn4D9nmCGHwA-9PJp_HXJsFQUJF52laEB5yGaTBrT8sETPyjod0V6RLMvJwt2YdM78LtulzLix-yKP5YlU7uw5dOnyYZ5XxUV2qkf_5V6vH6Cj-Aey1QJeNG8iHs2fIAbjbUlRcHcOusDco_gs2YFCtHe1QbR7FF9GKjPSlY-Y1U9XK1Ie8nY-qWS0M88Q6RrU_gBfcfmGxrnLDQ5cmiJEtbSXfKaaFJuSrpdolaUxdeIAXOS0Q7L90cwvTkw-d3p7SlcqA6TpOKykypQMRGp5xnKcJMBBKxCpVK58qGibVcmkTjp4oTy1QilRAMoZ1O7TwOrbTsMQywU_sUiA6YlCbTzODmNIuMjDO0VKASh_10yIYQdp8z122dc0e3UeQ-3s5E3pg2R9Pm3rQ5H8Kb_pl1U-XjSumjzkvydsRvc8fy5ViPWTaEV_1tHKvOQrK0q7qRwe0lE_iSTxqn6rtjPIuECLFxseNuvYCrA757p1x89_XAQwfreRwO4bjzzN_vdZUax733_ofWz64n_hzuRN55XZLTEQyqTW1fIH6r1Mt2sP4CH3c8YA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+longitudinal+circulating+tumor+DNA-based+model+associated+with+survival+in+metastatic+non-small-cell+lung+cancer&rft.jtitle=Nature+medicine&rft.au=Assaf%2C+Zoe+June+F.&rft.au=Zou%2C+Wei&rft.au=Fine%2C+Alexander+D.&rft.au=Socinski%2C+Mark+A.&rft.date=2023-04-01&rft.issn=1078-8956&rft.eissn=1546-170X&rft.volume=29&rft.issue=4&rft.spage=859&rft.epage=868&rft_id=info:doi/10.1038%2Fs41591-023-02226-6&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41591_023_02226_6 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-8956&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-8956&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-8956&client=summon |